Rituxan®
Rituximab

COORDINATING CARE

With an Infusion Center That Administers Rituxan

Referral Checklist

There are a few considerations to keep in mind when referring patients to an outside infusion center.

- ◯ **Identify** an infusion center
  - – You may visit the National Infusion Center Association's (NICA) locator infusioncenter.org/find-an-infusion-center to find one. This locator helps connect patients with infusion centers within their communities*
- ◯ **Check** to see if the infusion center is in your patient's health plan's network and follow the plan's referral process
- ◯ **Confirm** that the prescribing physician has privileges at the institution if it is a hospital-affiliated infusion center
- ◯ **Coordinate** communication between the center, your practice and the patient

What May Be Helpful to Send to the Infusion Center

The following information may be necessary; however, this is not intended to be an exhaustive list.

- ◯ **Patient demographics** (name, date of birth, address, phone number, copy of insurance card, emergency contact's name and phone number)
- ◯ **Patient records** (e.g., medication list, allergies, medications previously tried and failed, diagnosis, height and weight)
- ◯ **Referring physician's information** (name, National Provider Identifier [NPI], office contact, address, phone number)
- ◯ **Physician prescription for medication to be infused** (dose, schedule and pre-medications with physician's signature)

Talk With the Patient

Be sure the patient knows:

- ◯ **The infusion center's address and phone number**, as well as the date and time of the appointment(s)
- ◯ To call the infusion center **to confirm infusion preparations**, if any

*The NICA Infusion Center Locator is non-medication and non-disease specific, so it contains sites that may not infuse Rituxan or that may not be covered by a particular patient's health insurance. The NICA Infusion Center Locator may not represent a full list of all infusion sites. Genentech does not make any representations regarding the quality of, or insurance coverage for, infusion services provided at any particular infusion site.

Rituxan Indications

- Rituxan® (rituximab), in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more TNF antagonist therapies
- Rituxan, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)
- Rituxan is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris (PV)

For Important Safety Information, please see reverse and the accompanying Rituxan full Prescribing Information, including **BOXED WARNINGS**.

Genentech
A Member of the Roche Group

BOXED WARNINGS and Additional Important Safety Information

- **Infusion-Related Reactions: Rituxan administration can result in serious, including fatal infusion-related reactions. Deaths within 24 hours of Rituxan infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion. Monitor patients closely. Discontinue Rituxan infusion for severe reactions and provide medical treatment for Grade 3 or 4 infusion-related reactions.**
- **Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions can occur in patients receiving Rituxan.**
- **Hepatitis B Virus (HBV) Reactivation: HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with Rituxan. Discontinue Rituxan and concomitant medications in the event of HBV reactivation.**
- **Progressive Multifocal Leukoencephalopathy (PML), including fatal PML, can occur in patients receiving Rituxan.**

Rituxan administration can also result in additional serious, including fatal, adverse reactions including:

- Tumor lysis syndrome (TLS): Administer aggressive intravenous hydration, anti-hyperuricemic agents, monitor renal function
- Infections: Withhold Rituxan and institute appropriate anti-infective therapy. Rituxan is not recommended for use in patients with severe, active infections
- Cardiovascular adverse reactions: Discontinue infusions in case of serious or life-threatening events
- Renal toxicity: Discontinue in patients with rising serum creatinine or oliguria
- Bowel obstruction and perforation: Consider and evaluate for abdominal pain, vomiting, or related symptoms
- Immunizations: Live virus vaccinations prior to or during Rituxan treatment are not recommended
- Embryo-Fetal toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and use of effective contraception
- Patients with RA should be closely observed for signs of infection if biologic agents and/or DMARDs other than methotrexate are used concomitantly
- The use of Rituxan in patients with RA who have not had prior inadequate response to one or more TNF antagonists is not recommended
- Use of concomitant immunosuppressants other than corticosteroids has not been studied in GPA, MPA, or PV patients exhibiting peripheral B-cell depletion following treatment with Rituxan
- Most common adverse reactions in patients with RA were upper respiratory tract infection, nasopharyngitis, urinary tract infection, and bronchitis. Other important adverse reactions include infusion-related reactions, serious infections, and cardiovascular events
- Most common adverse reactions in patients with GPA & MPA were infections, nausea, diarrhea, headache, muscle spasms, anemia, peripheral edema, and infusion-related reactions
- Most common adverse reactions in patients with PV were infusion-related reactions, depression, upper respiratory tract infection/nasopharyngitis, and headache. Other important adverse reactions include infections

For additional Important Safety Information, please see the Rituxan full Prescribing Information, including **BOXED WARNINGS.**

Attention Healthcare Provider: Provide Medication Guide to patient prior to Rituxan infusion.

One Number Can Connect You to All of the Help We Offer to Patients Prescribed Genentech Medicines

Call **(877) GENENTECH**/(877) 436-3683
with questions or to get started.

Genentech | Biogen

Rituxan®
Rituximab